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Abstract
This retrospective study attempts to establish if a correlation exists between osteoporosis and hematopoiesis before and after
adjuvant chemotherapy in the context of non-metastatic breast cancer. Osteoporosis is interpreted both as a direct marker of
osteoblastic decline and as an indirect marker of increased bone marrow adiposity within the hematopoietic microenvironment.
Patients from the BCentre du Sein^ at CHUV (Centre Hospitalier Universitaire Vaudois) undergoing adjuvant chemotherapy were
included in this study. Evolution of blood counts was studied in correlation with the osteoporosis status. Toxicity of chemotherapy
was coded according to published probability of febrile neutropenia. One hundred forty-three women were included: mean age
52.1 ± 12.5 years, mean BMI (body mass index) 24.4 ± 4.1. BMD (bone mineral density) scored osteoporotic in 32% and
osteopenic in 45%. Prior to chemotherapy, BMD was positively correlated with neutrophil (p < 0.001) and thrombocyte (p =
0.01) count; TBS (trabecular bone score) was not correlated with blood count. After the first cycle of chemotherapy, an increase of
one point in TBS correlated with a decrease of 57% on the time to reach leucocyte nadir (p = 0.004). There was a positive
correlation between BMD and risk of infection (p < 0.001). Our data demonstrates an association between osteoporosis and lower
blood counts in a younger cohort than previously published, extending it for the first time to neutrophil counts in females. Our
results suggest that the healthier the bone, the earlier the lowest leucocyte count value, prompting further research on this area.
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Introduction
Hematopoietic stem cell niche
Hematopoiesis is the process by which precursor and mature
blood cells are produced by hematopoietic stem cells (HSCs)
within the adult bone marrow. In adults, the hematopoietic
marrow resides within the axial skeleton and the proximal
epiphysis of the femur and the humerus. In these areas, the
marrow consists of 10–90% fat depending on age. In fact, it is
estimated that the bone marrow adipose tissue represents
around 1 to 1.5 kg in a healthy adult [1, 2].
The HSC niche, located within the bone marrow, is critical
for the maintenance of the HSC. The niche is composed of
different cells including osteoblasts, mesenchymal stromal
cells, perivascular cells, and adipocytes [3, 4].
Osteoblasts have a regulatory role in the HSC niche and sup-
port maintenance of the most primitive HSCs. Osteoblasts are a
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key element for the myeloid lineage as murine osteoblasts have
been shown to produceG-CSF (granulocyte colony-stimulating
factor), M-CSF (macrophage colony-stimulating factor), GM-
CSF (granulocyte-macrophage colony-stimulating factor), IL-1
(interleukin-1), IL-6 (interleukin-6) among other cytokines that
supportHSCproliferation [5].At the same time, osteoblasts also
produce inhibitorymolecules, such as osteopontin, that limit he-
matopoietic replication and have an overall supporting role in
HSC long-termmaintenance [5–10].
Adipocytes are important components of the hematopoietic
microenvironment. Although long considered passive space
fillers within the bone marrow, they also secret cytokines with
mixed hematopoetic activity, such as neuropilin-1,
adiponectin, and leptin. In mice, fully differentiated adipo-
cytes have been shown to have a negative regulatory effect
on HSC proliferation in the context of stress hematopoiesis
and post-transplantation aplasia, while both in mice and hu-
man they support the survival of the most primitive hemato-
poietic stem cells [11–15].
Osteoporosis
Osteoporosis is a skeletal disorder characterized by compro-
mised bone strength and microarchitectural deterioration. The
bone mineral density (BMD) is evaluated by dual-energy X-
ray absorptiometry (DXA). The result of the BMD is given as
a T-score relative to normal values from a pool of a healthy 25-
year-old population. Osteoporosis is defined by a T-score be-
low − 2.5 standard deviations (SD) [16]. The trabecular bone
score (TBS) is a gray-level textural index, derived from lum-
bar spine DXA images, that is correlated with parameters
reflecting bone microarchitecture [17]. TBS provides skeletal
information that is not captured with standard BMD measure-
ments. A low TBS is consistently associated with an increased
risk of prevalent and incident fractures. Therefore, bone com-
position can be partially deducted from T-score and TBS.
Osteoporosis, at the cellular level, can be explained by an
imbalanced activity of osteoblasts and osteoclasts. This pro-
cess results in an increase of the bone turnover and a trabecular
bone loss which in turn results in increased adipocyte content
[16, 18–23]. Thus, osteoporosis is interpreted here both as a
direct marker of osteoblastic decline and as an indirect marker
of increased bone marrow adiposity.
Osteoporosis and breast cancer
Several studies have suggested an inverse relationship be-
tween BMD and breast cancer incidence [24]. Moreover, can-
cer treatment that reduces estrogens levels affects negatively
BMD in premenopausal women [25]. Interestingly, BMD loss
in premenopausal women during 6 months’ adjuvant systemic
chemotherapy seems to be independent of changes in ovarian
function [26]. Postmenopausal women with breast cancer who
received adjuvant chemotherapy had lower BMD than those
who did not [27]. It is estimated that postmenopausal women
with breast cancer lose 2–3 fold more BMD, in comparison
with healthy postmenopausal women [28].
We thus decided to test whether there is a correlation be-
tween osteoporosis and hematopoiesis upon stress hematopoi-
esis before and after adjuvant chemotherapy, in the context of
a breast cancer cohort.
Methods
Cohort of breast cancer patients:
All women treated for localized breast cancer at the Centre
Hospitalier Universitaire Vaudois (CHUV), Lausanne,
Switzerland, between August 2008 and July 2015 were evalu-
ated for this retrospective study. The women were included if
they (1) had a non-metastatic breast cancer at the time of diag-
nosis, (2) belonged to the BCentre du Sein^ database with no
document attesting disagreement to share their data for research
projects, and (3) received chemotherapy. BMD was evaluated
by DXA before or at onset of adjuvant endocrine therapy.
The criteria for exclusion were absence of available BMD
measurement 3 years prior or following the diagnosis, absence
of available laboratory values following chemotherapy, any
prior chemotherapy, BMI > 35, history of hematological dis-
orders or of active hematological disease, active second ma-
lignancy concomitant to breast cancer, or moderate to severe
renal impartment. Some patients received endocrine therapy
after completion of the chemotherapy treatment. As blood
counts are not influenced by endocrine therapy, this was not
an exclusion criteria.
Bone parameters
BMD was measured on the femoral neck, total femur, and
lumbar spine and TBS was measured at lumbar spine L1 to
L4. According to the BMDvalues, osteoporosis was defined if
any of the three locations obtained a T-score < − 2.5 SD,
osteopenia as a T-score between − 1.0 and − 2.5 SD, normal
as a T-score > − 1.0 SD [16].
The following normal range for TBS values was used:
TBS > 1.310 was considered to be normal, TBS between
1.230 and 1.310 was considered to be consistent with
partially degraded microarchitecture, and TBS < 1.230 de-
fined degraded microarchitecture.
Collected data
We collected the identification code of the patients, date of
birth, diagnosis, date of diagnosis, type of chemotherapy,
starting date of chemotherapy, T-score, and TBS values.
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To study hematological recovery, all available blood counts
between 1 week prior to the first cycle of chemotherapy and
the first day of the second cycle of chemotherapy were col-
lected. The incidence of infection between the first day of
chemotherapy and the first day of the second cycle of chemo-
therapy was also recorded.
Confounding factors taken into account for the multivariate
analysis were the age at the time of treatment, the use of G-
CSF, and the type of chemotherapy, which was graded accord-
ing to hematological toxicity.
To code the toxicity of the chemotherapy, we took advan-
tage of previous literature discussing the recommended use of
G-CSF during chemotherapy for breast cancer [29]. Zielinski
et al. created a table with the associated risk of febrile neutro-
penia for each standard adjuvant breast cancer chemotherapy
regime (Table 1). The risk is given as the percentage of pa-
tients who will present febrile neutropenia without G-CSF.
The clinical trials data of each chemotherapy regime were
used to generate the table with the risk of febrile neutropenia.
We used this reference to code the hematological toxicity
of the different chemotherapy using the published risk of fe-
brile neutropenia for each chemotherapy regime as a continu-
ous variable to adjust for intensity of hematological toxicity in
our multivariate analysis.
Response variables
To establish the response variables, we collected both the date
and the absolute value for neutrophil, leucocyte, and throm-
bocyte nadir. We calculated the difference between the starting
count and the neutrophil, leucocyte, and thrombocyte count at
nadir, as well as the rate of infection.
Statistical analysis
For the analysis of the blood count before chemotherapy, lin-
ear regressions were performed.
The univariate analysis was performed using GraphPad
Prism version 7.0a for Mac OS X, GraphPad Software, San
Diego California USA, www.graphpad.com. The multivariate
analysis was performed using R (version 3.3.1).
For the three variables Bdate for neutrophil, leucocyte and
thrombocyte nadir,^ both a Poisson regression and a linear
regression were performed and both gave similar results. For
the six variables Bvalue of neutrophil, leucocyte and thrombo-
cyte nadir^ and Bdifference between the starting count and the
neutrophil, leucocyte and thrombocyte count at nadir,^ a lin-
ear regression was performed. For the variable Binfection,^ a
logistic regression was performed. Each regression was per-
formed four times changing the explicative variable: TBS
score continuous, TBS score categorical, T-score continuous,
and T-score categorical. Each regression was adjusted for the
variables age, G-CSF, and toxicity of chemotherapy. Some
variables showed missing values. Complete case analyses
were performed.
The quality control of the regressions was done using re-
sidual versus fitted predicted values.
Ethical committee
All procedures were in accordance with the ethical standards
of the responsible committee on human experimentation and
in accordance with the 1975 Helsinki declaration as revised in
2008. The local ethical commission approved the study (CER-
VD, Lausanne, Switzerland). For this type of study, specific
Table 1 Frequency of adjuvant
chemotherapy regimes in our
cohort. The corresponding risk of
febrile neutropenia according to
Zielinski et al. was used to code
the toxicity of the chemotherapy
regime as a continuous variable
Chemotherapy Risk of febrile neutropenia
during cycle of chemotherapy, (%)
(adapted from ref. [21])
Number of patients
(n = 143), (%)
G-CSF treatment administered
during the 1st cycle of
chemotherapy (n = 143), (%)
Doc-Car 13 3 (2.1) 3 (100)
FEC-Doc 11 42 (29.4) 7 (17)
FEC 6 2 (1.4) 0 (0)
AC-Pac 5 1 (0.7) 1 (100)
Cap-Doc 5 1 (0.7) 0 (0)
EC 5 4 (2.8) 3 (75)
ECP 5 15 (10.5) 9 (60)
FEC-Pac 5 1 (0.7) 0 (0)
TC 5 66 (46.2) 24 (36)
AC 3 2 (1.4) 0 (0)
Paclitaxel 2 6 (4.2) 0 (0)
Doc-Car docetaxel–carboplatine–trastuzumab, FEC-Doc 5-fluorouracil–epirubicin–cyclophosphamide–docetax-
el, FEC 5-fluorouracil–epirubicin–cyclophosphamide, AC-Pac doxorubicin–cyclophosphamide–paclitaxel,Cap-
Doc capecitabine-docetaxel, EC epirubicin–cyclophosphamide, ECP epirubicin–cyclophosphamide–paclitaxel,
FEC-Pac 5-fluorouracil–epirubicin–cyclophosphamide–paclitaxel, TC docetaxel–cyclophosphamide, AC doxo-
rubicin–cyclophosphamide
Ann Hematol (2018) 97:309–317 311
consent was not required. Patients having provided a docu-
ment attesting disagreement to share their medical data for
research projects were excluded.
Results
Characteristics of the cohort
The baseline characteristics of the 143 included women
are summarized in Table 2. Active comorbidities were
relatively rare in the cohort. The three more frequent ac-
tive comorbidities were: arterial hypertension (23 patients,
17%), hypothyroidism (12, 8%), and diabetes (4, 3%).
Treatment of hypertension, hypothyroidism, and diabetes
were similarly distributed among the healthy versus
osteopenic/osteoporotic groups. No patient was excluded
after analysis (Fig. 1).
Blood counts before chemotherapy
The blood counts before chemotherapy were analyzed accord-
ing to T-score and TBS values. Our results indicate that an
increase of one point in the T-score is associated with an in-
crease of 13.51 G/l platelets and 0.644 G/l neutrophils within
our cohort (Fig. 2).
No significant trends were found for the association of
blood counts and TBS score before chemotherapy. Subgroup
analysis using menopausal status (premenopausal and post-
menopausal) did not attain a significant association between
T-score and blood counts within our cohort.
Blood counts after first cycle of chemotherapy
The evolution of the blood counts during the first cycle of
chemotherapy was analyzed. Toxicity of chemotherapy was
coded according to risk of febrile neutropenia as described in
the methods section.
The average day of leucocyte nadir was 9.9 ± 4.2 days.
An increase of one point in TBS correlates with a decrease
of 57% of the mean day count on the time for leucocyte
nadir with a p value of 0.004 (Table 3), such that average
day of leucocyte nadir was 10 days for the degraded
microarchitecture group and 9.82 days for the normal
microarchitecture group.
Rate of infection after first cycle of chemotherapy
From our analysis, rate of infection was also significantly
correlated with the T-score with an odd ratio of 2.08 and a p
value of 0.000989. TBS values did not significantly correlate
with the rate of infection (Table 4).
Discussion
The results of our retrospective study indicate that, before
chemotherapy, a higher T-score is associated with a higher
neutrophil and thrombocyte count. After the first cycle of
chemotherapy, our results suggest that a higher TBS score
significantly correlates with a faster drop of the leucocyte
count, and that a higher T-score correlates with a higher risk
of infection.
There are several published studies describing a link be-
tween osteoporosis and overall lower blood counts in post-
menopausal women or the elderly [30–32]. Of note, a recent
study has found a paradoxical increase in the neutrophil
counts of osteoporotic elderly men while monocyte and lym-
phocyte counts were decreased [33]. We chose to analyze our
data to see if the same pattern was found. It is important to
note that our patients were younger (52 years in mean), leaner
(no BMI > 35), were not free of disease, as the breast cancer
diagnosis was recently given, and they had recently recovered
from lumpectomy/mastectomy. However, we excluded all pa-
tients with metastatic disease, making a systemic repercussion
of local breast cancer less likely. We thus consider that prior to
chemotherapy our cohort was subject to the minor hematopoi-
etic stress of surgery, which also added heterogeneity to he-
moglobin values given differences in blood loss during the
Table 2 Characteristics of the patients (n = 143) from the data base,
osteoporotic defined by a T-score < − 2.5 or pathological fracture,
osteopenia defined by a T-score between − 2.5 and − 1, normal de-
fined by a T-score > − 1. Degraded microarchitecture defined by a
TBS score < 1.2, a partially degraded microarchitecture is defined
by a TBS score between 1.2 and 1.35, a normal microarchitecture is
defined by a TBS score > 1.35
Characteristics Values
Age at the start of chemotherapy (years), mean ± SD 52.13 ± 12.47
T-score
Osteoporotic, n (%) 33 (32)
Osteopenia, n (%) 64 (45)
Normal, n (%) 46 (23)
TBS, mean ± SD 1.33 ± 0.12
Degraded microarchitecture, n (%) 20 (15)
Partially degraded microarchitecture, n (%) 49 (35)
Normal, n (%) 70 (50)
Hormonal status at the start of chemotherapy
Premenopausal, n (%) 78 (55)
Postmenopausal, n (%) 60 (42)
Undetermined, n (%) 5 (3)
BMI at the start of chemotherapy (kg/m2), mean ± SD 24.47 ± 4.05
G-CSF administration during 1st of chemotherapy, n (%) 47 (33)
Infections during 1st cycle of chemotherapy, n (%) 43 (30)
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CHUV breast cancer register (approx imat ively
1000 patients at the t ime of t he study)
250 patients who received che motherapy,and
had no metastases
80 with no bone density exam ± 3 years
170 with bone density exam ± 3 years
750 who either had metastases or did not receive
adjuvant chemot herapy
9 with a BMI > 35
150 with a BMI 35
5 with medical comorbidit y exc lusion cr iteria:
- 1 renal t ransplant
- 1 act ive cancer at the t ime of diagnostic
- 1 suspic ion of bone metastasis confirmed later
- 2 hemochromatosis
145 with no medical co morbid it y exc lusion
cr iteria
11 treated outs ide of the CHUV
159 treated at the CHUV
1 male
144 females
1 received only endocrine therapy
143 received chemotherapy ±
endocrine therapy
Fig. 1 Exclusion process, CHUV,
Centre Hospitalier Universitaire
Vaudois: BMI, body mass index
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Fig. 2 Blood cell counts according to T-score values. As BMD (bone marrow density) decreases neutrophils and thrombocytes also decrease (linear
regression, p < 0.05), Hb ns
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procedure. Congruent with the literature, our analysis found a
positive association between T-score and both thrombocyte
and neutrophil counts. Given their very short half-life in cir-
culation, neutrophils best reflect the ongoing function of the
marrow upon stress hematopoiesis.
All previously published data refers to elderly or postmen-
opausal cohorts. Subgroup analysis within our cohort did not
find a significant association within the postmenopausal sub-
group, probably due to the reduced number of postmenopaus-
al patients (n = 60). When comparing blood counts with TBS
score instead of T-score, no significant association was ob-
served. This difference may be explained by the fact that
BMD evaluates the total bone mineral content, and TBS the
organization of trabeculae. Thus, our data demonstrates an
association between osteoporosis and lower blood counts in
a younger cohort than previously published, showing for the
first time decreased thrombocyte and neutrophil counts in os-
teoporotic women subject to a minor hematopoietic stress.
Specifically, we observed an average minimum difference of
20 G/l on the thrombocyte count and 1.0 G/l on the neutrophil
count between patients with normal bone and osteoporotic
bone.
As bone health affects the initial blood counts and as oste-
oporosis is partially reversible, our study suggests that prompt
treatment of osteoporosis may be beneficial to patients under-
going chemotherapy to minimize the hematopoietic toxicity.
Therefore, bone assessment may be indicated before or strictly
at the start of chemotherapy. Injectable antiresorptive treat-
ments (bisphosphonates, denosumab) very rapidly reduce
the activity of osteoclasts. Our work should thus prompt fur-
ther studies on (i) the effect of antiresorptive treatments on
complete blood counts in non-oncological patients and (ii)
the pertinence of early osteoporotic treatment in oncological
patients. Retrospective studies could address whether treat-
ment of osteoporosis normalizes blood counts. The pertinence
to the oncological settings should be tested by a randomized
Table 3 A Poisson regression
multivariate, TBS, B Poisson
regression multivariate, T-score
A
TBS, multivariate (Poisson regression) n = 139 Day of leucocyte nadir
Risk ratio 2.5% 97.5% p value
TBS 0.43 0.24 0.76 0.0039
Age at the start of chemotherapy 0.99 0.99 1.00 0.05
G-CSF administration 0.84 0.75 0.95 0.01
Toxicity of the chemotherapy 1.04 1.02 1.06 0.000046
B
T-score, multivariate (Poisson regression) n = 143 Day of leucocyte nadir
Risk ratio 2.5% 97.5% p value
T-score 1.00 0.95 1.05 0.91
Age at the start of chemotherapy 1.00 0.99 1.00 0.45
G-CSF administration 0.84 0.74 0.95 0.0043
Toxicity of the chemotherapy 1.03 1.02 1.05 0.0002
Table 4 A logistical regression
multivariate, T-score, B logisitical
regression multivariate, TBS
A
T-score, multivariate (logistical regression) n = 143 Infections
Odds ratio 2.5% 97.5% p value
T-score 2.08 1.37 3.28 0.00099
Age at the start of chemotherapy 1.01 0.98 1.05 0.43
G-CSF administration 3.94 1.74 9.25 0.0012
Toxicity of the chemotherapy 0.83 0.71 0.96 0.02
B
TBS, multivariate (logistical regression) n = 139 Infections
Odds ratio 2.5% 97.5% p value
TBS 10.08 0.18 654.67 0.27
Age at the start of chemotherapy 1.00 0.96 1.04 0.98
G-CSF administration 4.00 1.79 9.25 0.00089
Toxicity of the chemotherapy 0.86 0.73 0.98 0.04
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controlled study with early administration of bisphosphonates
already approved for multiple myeloma or bone metastatic
disease.
Regarding blood counts after the first cycle of chemother-
apy, our analysis suggests that a healthier bone is associated
with a more rapid drop in the total leucocyte count, or in other
words, that osteoporosis slows down the leucocyte drop im-
mediately after chemotherapy. This result is unexpected. The
osteoblasts and the perivascular cells have been shown to have
a supportive effect on hematopoiesis. In the osteoporotic bone,
both the osteoblast count and microvasculature are reduced
and the adipocyte load increased. Therefore, we had expected
to see a negative effect of osteoporosis on blood counts post-
chemotherapy, as it has been described in homeostatic condi-
tions prior to chemotherapy. Our results could have different
interpretations.
The osteoporotic microenvironment may indeed be ac-
tively protective to the hematopoietic progenitors imme-
diately after chemotherapy. Alternative explanations in-
clude that the adipocytes within the bone marrow might
mediate a non-specific protective effect by facilitating de-
layed drug release. In fact, obesity is associated with low-
er toxicity during chemotherapy for gynecological can-
cers in part due to the delayed drug release for drugs with
high distribution volumes [34, 35]. Within the bone mar-
row, increased adipocytic mass could thus possibly trans-
late into a lower bolus dose but a longer exposition time
upon chemotherapy, especially for chemotherapy agents
with a high volume of distribution. This hypothesis is
compatible with the increased adipocytic content of the
marrow after chemotherapy, a phenomenon recently char-
acterized in vivo through magnetic resonance imaging
upon carboplatin with paclitaxel treatment for ovarian
cancer [36].
Additionally, we cannot exclude a sampling bias. Since the
depth of the leucocyte drop was not significantly different
between osteoporotic and non-osteoporotic patients, even
though non-osteoporotic patients had significantly higher
blood counts before chemotherapy, the earlier nadir of non-
osteoporotic patients may just reflect a faster rate of hemato-
logical recovery in patients with healthier bone. Our results
should prompt further studies in a cohort with more abundant
data points for the blood count recovery.
Finally, we observed a positive association between T-
score and the rate of infection. This result is also unexpected,
but it is congruent with the slower drop of leucocytes in oste-
oporotic women, which could indicate a protective role of the
osteoporotic microenvironment for infection. We could not
however measure the duration of neutropenia and therefore
could not test if a slower fall is associated with a shorter period
of neutropenia.
Several sources of bias could also explain the observed
outcome for infection. The quality of the data was lower
for the qualitative analysis of infection than for the quan-
titative analysis of blood counts. First, the G-CSF treat-
ment was only coded yes/no, as information was not al-
ways available to know whether it was given as primary
or secondary prophylaxis of severe neutropenia. Second,
the infections were recorded but no distinction was made
on the severity. Of note, age was not a significant expli-
cative variable anymore in the multivariate analysis for
rate of infection. It is thus likely that other variables in-
fluence the infection rate in our cohort.
It is interesting to note that hematopoietic parameters at
start correlate only with BMD and later only with TBS.
Those results could be simply explained by a lack of data
to reach significance with both parameters. However, a
biological explanation is also possible. Spine TBS is sig-
nificantly correlated with measurements of volumetric
densities, cortical thickness, and whole bone stiffness at
the radius and at the tibia [16]. These findings were
assessed using transiliac bone biopsies, and suggest that
TBS is capable of mapping the structure of trabecular
bone [37]. Moreover, the correlation between LS-BMD
and TBS is weak (r = 0.32), indicating that the two param-
eters were measuring different skeletal properties [37].
Conversely, LS-BMD and hip BMD were highly correlat-
ed (r = 0.72). The difference between BMD and TBS ob-
served in our study could thus be explained by different
niches being evolved in homeostatic hematopoiesis and
stress hematopoiesis as TBS and BMD describe different
bone components.
Other limitations of our cohort should be addressed. A
higher number of patients might have been necessary to draw
more conclusive results. However, extension of the study pe-
riod would have brought more variability in the treatment
options, as the treatment of breast cancer is evolving quickly.
From the included patients of the BCentre du Sein,^ a signif-
icant number (n = 80) did not have BMD and were therefore
excluded. Also, a low number of postmenopausal women
(n = 60) were part of the cohort, which limited subgroup anal-
ysis. Unfortunately, we did not have differential blood count
for all patients, which most likely explains why some results
including neutrophil counts post-chemotherapy did not reach
statistical significance. Furthermore, due to limited blood
counts, no recovery curve was calculable. Other parameters
such as delay of the second cycle of chemotherapy and need
for growth factors to prompt blood recovery were too rare to
permit meaningful statistical analysis (one chemotherapy de-
layed, 19 patients received G-CSF because of low blood
count).
Nevertheless, our overall observations underline that, as
predicted by recent research on the bone marrow hemato-
poietic stem cell niche, differences in the osteoporotic bone
microenvironment translate into altered dynamics upon he-
matopoietic stress. As other authors, we observed a
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positive correlation between T-score and blood counts in
homeostasis or minor hematopoietic stress. After the first
cycle of chemotherapy, a strong stressor for the bone mar-
row, we observed a slower fall of the leucocyte count in
osteoporotic patients. Further studies are needed to clarify
how bone physiopathology affects human hematopoiesis in
different contexts both during homeostasis and stress
hematopoiesis.
Conclusion
The results of our retrospective monocentric study indicate
that, before chemotherapy, a higher T-score is associated with
a higher count in neutrophils and thrombocytes. This correla-
tion was specific for T-score; no trend was observed when
TBS was considered. No significant association was observed
for the hemoglobin in our post-surgery cohort.
After the first cycle of chemotherapy, our results suggest
that a higher TBS significantly correlates with a faster drop
on the leucocyte count, and that a higher T-score correlates
with a higher risk of infection. The rate of hematological
recovery was not measurable due to insufficient data
points. Blood counts following chemotherapy suggest that
the healthier the bone, the earlier the lowest leucocyte
count value.
Further studies are needed to better understand the kinetics
of blood cell count recovery after chemotherapy as related to
bone health.
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